ClinicalTrials.gg
TerminatedNCT01198873ODYSSEUSUpdated Feb 12, 2013Results posted

Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement

A Phase 4 interventional study of Dronedarone and Placebo (for Dronedarone) in Atrial Fibrillation, sponsored by Sanofi. Terminated at 57 sites in 2 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2013-02-12.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.

Enrollment
20th of 26
76 · median 164
Started
2010
with 8 others
Phase 4
11 of 26
2 open now
Registered
13th of 26
by date
Lead sponsor
13 of 26
Sanofi

Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 20th largest by enrollment, is one of 9 that started in 2010, is one of 11 in phase 4, and was the 13th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dronedarone

Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing dronedarone in Atrial Fibrillation, or all of them as a file.
02

Study summary

Primary Objective:

  • Evaluate the effect of dronedarone versus placebo (standard therapy) in slowing the progression of adverse left atrial remodeling in patients with atrial fibrillation (AF) following 12 months of treatment.

Secondary Objectives:

  • Evaluate the effects of dronedarone versus placebo on left atrial function;
  • Evaluate the effects of dronedarone versus placebo on left atrial dimension;
  • Evaluate the effects of dronedarone versus placebo on left ventricular function (LVEF, E, E', A, E/E')
  • Evaluate the safety and tolerability of dronedarone.
Read the detailed description

The planned total study period per participant was 12 months and 3 weeks broken down as follows:

  • Screening period: up to 1 week;
  • Treatment period: 12 months;
  • Follow-up period: 2 weeks.
03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written and Health Insurance Portability and Accountability Act (HIPAA) Authorization;
  • Nonpermanent AF or AF/Atrial Flutter (AFL) documented electrocardiographically by both AF (or AF/AFL) and sinus rhythm within the prior 12 months;
  • At screening, sinus rhythm and Left Atrial Volume index (LAVi) ≥32 mL/m2 based on 2D-echocardiography;
  • At least one of the following cardiovascular (CV) risk factors: Age >70 years at start of screening, hypertension, diabetes mellitus, prior CV accident (stroke or ) or systemic embolism, or \<0.40.

Exclusion criteria

Exclusion criteria:

  • Permanent AF defined as continuous AF for 6 months or longer;
  • Persistent AF defined as sustained AF >7 days duration and/or requiring cardioversion in the 4 weeks before screening;
  • Prior valvular heart surgery or significant valvular heart disease including rheumatic heart disease or acquired valvular heart disease;
  • Aortic or mitral regurgitation greater than mild (>1+) or any degree of mitral stenosis at the screening echocardiogram;
  • Myocardial infarction within the 6 months prior to screening or stroke within 2 months prior to screening;
  • Pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy devices placed within the 6 months prior to screening or at anytime during the study;
  • Ongoing potentially dangerous symptoms when in AF/AFL such as angina pectoris, , stroke, syncope as judged by the Investigator;
  • Cardiac ablative procedure or cardiac surgery within 3 months prior to screening, or percutaneous coronary intervention within 4 weeks prior to screening;
  • Need for concomitant medication that is prohibited in this trial, and would preclude the use of the study drug during the planned study period including the following:

    • Antiarrhythmics (eg, amiodarone, flecainide, propafenone, quinidine, disopyramide, dofetilide, sotalol);
    • Drugs or products that are strong inhibitors of (eg, ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, ritonavir, and grapefruit juice);
    • Drugs that are inducers of CYP3A (eg, rifampin, phenobarbital, carbamazepine, phenytoin, and St John's wort);
  • Bazett interval ≥500 msec on the screening ;
  • Bradycardia \<50 bpm and/or PR interval ≥0.28 sec on the screening ECG unless the patient has a functional pacemaker;
  • (NYHA) Class IV heart failure or NYHA Class II or III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic within 4 weeks prior to screening.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Dronedarone

    Dronedarone 400 mg twice a day

    Drug: Dronedarone

  • Placebo comparator
    Placebo

    Placebo (for Dronedarone) twice a day

    Drug: Placebo (for Dronedarone)

Interventions

  • Film-coated tablet Oral administration under fed conditions (during breakfast and dinner)

    Also known as: Multaq®, SR33589

  • DrugPlacebo (for Dronedarone)

    film-coated tablet strictly identical in appearance Oral administration under fed conditions (during breakfast and dinner)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Left Atrial Volume Index (LAVi)

    Left Atrial Volume index (LAVi) was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.

    Time frame: baseline (before randomization) and post-baseline (after 3-12 months of treatment)

Secondary outcomes

  1. Changes From Baseline in Left Atrial Function

    left atrial (LA) function was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.

    Time frame: baseline (before randomization) and post-baseline (after 3-12 months of treatment)

  2. Changes From Baseline in Left Atrial Dimension

    Maximal left atrial diameter in the anteroposterior dimension was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last drug intake and data were included in the analysis.

    Time frame: baseline (before randomization) and post-baseline (after 3-12 months of treatment)

  3. Changes From Baseline in Left Ventricular Ejection Fraction (LVEF)

    Left Ventricular Ejection Fraction (LVEF) was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last drug intake and data were included in the analysis.

    Time frame: baseline (before randomization) and post-baseline (after 3-12 months of treatment)

  4. Changes From Baseline in Left Ventricular Function

    left ventricular (LV) function was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.

    Time frame: baseline (before randomization) and post-baseline (after 3-12 months of treatment)

07

Results

Posted Feb 12, 2013
Limitations and caveats
Due to the early termination of the study, results should be cautiously interpreted. Indeed the number of participants was lower than planned (76 instead of 334) and the treatment period was shorter than planned (6 months instead of 12 months).

Participant flow

Recruitment initiated in September 2010 was discontinued in September, 2011 due to significantly lower than planned enrollment with no feasibility to complete the trial within reasonable, meaningful timelines. At that time 57 sites in US and Canada had screened at least one patient.

Participant flow — Overall Study
MilestonePlaceboDronedarone
Started4135
Treated4135
Evaluable for efficacy3326
Completed43
Not completed3732
Withdrew: Adverse event47
Withdrew: Study closure2923
Withdrew: Other than above42

Outcome measures

PrimaryChange From Baseline in Left Atrial Volume Index (LAVi)

Left Atrial Volume index (LAVi) was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.

Time frame:
baseline (before randomization) and post-baseline (after 3-12 months of treatment)
Reported as:
Mean · mililiters/m2
Change From Baseline in Left Atrial Volume Index (LAVi)
mililiters/m2PlaceboDronedarone
Baseline (n =33, 26)37.555 ± 5.89937.715 ± 6.597
Post-baseline (n =32, 26)29.191 ± 5.99430.823 ± 5.364
Change from baseline (n =32, 26)-8.438 ± 4.743-6.892 ± 5.759
SecondaryChanges From Baseline in Left Atrial Function

left atrial (LA) function was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.

Time frame:
baseline (before randomization) and post-baseline (after 3-12 months of treatment)
Reported as:
Mean · mililiters
Changes From Baseline in Left Atrial Function
mililitersPlaceboDronedarone
LA passive emptying volume (n = 19, 19)-10.783 ± 7.798-4.566 ± 9.094
LA conduit volume (n =29, 25)-1.366 ± 5.652-0.764 ± 5.759
LA active emptying volume (n = 19, 19)-0.052 ± 4.7071.198 ± 5.695
LA passive emptying fraction (n = 19, 19)-0.074 ± 0.074-0.019 ± 0.117
LA active emptying fraction (n = 19, 19)0.057 ± 0.1040.067 ± 0.105
SecondaryChanges From Baseline in Left Atrial Dimension

Maximal left atrial diameter in the anteroposterior dimension was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last drug intake and data were included in the analysis.

Time frame:
baseline (before randomization) and post-baseline (after 3-12 months of treatment)
Reported as:
Mean · centimeters
Changes From Baseline in Left Atrial Dimension
centimetersPlaceboDronedarone
Changes From Baseline in Left Atrial Dimension-0.124 ± 0.188-0.166 ± 0.161
SecondaryChanges From Baseline in Left Ventricular Ejection Fraction (LVEF)

Left Ventricular Ejection Fraction (LVEF) was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last drug intake and data were included in the analysis.

Time frame:
baseline (before randomization) and post-baseline (after 3-12 months of treatment)
Reported as:
Mean · percentage of blood pumped out
Changes From Baseline in Left Ventricular Ejection Fraction (LVEF)
percentage of blood pumped outPlaceboDronedarone
Changes From Baseline in Left Ventricular Ejection Fraction (LVEF)0.948 ± 3.3331.147 ± 3.997
SecondaryChanges From Baseline in Left Ventricular Function

left ventricular (LV) function was assessed at baseline and after 12 months treatment using 2-D echocardiography and interpreted blindly via a central Echocardiography Core Lab. Participants who discontinued after completing at least 3 months of treatment were assessed after last study drug intake and data were included in the analysis.

Time frame:
baseline (before randomization) and post-baseline (after 3-12 months of treatment)
Reported as:
Mean · centimeters/second
Changes From Baseline in Left Ventricular Function
centimeters/secondPlaceboDronedarone
Peak early diastolic transmitral flow velocity (E)5.165 ± 15.440-10.497 ± 27.890
Mitral annular velocity (E')0.847 ± 2.002-0.119 ± 1.845
Peak late diastolic transmitral flow velocity (A)0.076 ± 11.6744.319 ± 14.275
E/E' ratio-0.787 ± 3.346-1.443 ± 4.288

Adverse events

Collected over All Adverse Events (AE) were collected regardless of seriousness or relationship to the drug in the period spanning from signature of the Informed Consent Form up to the last visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/41 (2.4%)5/41 (12.2%)
Dronedarone—5/35 (14.3%)14/35 (40%)
Most frequent serious events
Most frequent serious events
EventPlaceboDronedarone
Cardiac failure congestiveCardiac disorders0/411/35
Pleural effusionRespiratory, thoracic and mediastinal disorders0/411/35
Gastrointestinal haemorrhageGastrointestinal disorders0/411/35
Pancreatic cystGastrointestinal disorders0/411/35
Gouty arthritisMusculoskeletal and connective tissue disorders0/411/35
Renal failure acuteRenal and urinary disorders0/411/35
AstheniaGeneral disorders0/411/35
Femoral neck fractureInjury, poisoning and procedural complications0/411/35
Angina pectorisCardiac disorders1/410/35
Atrial fibrillationCardiac disorders1/410/35
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboDronedarone
DiarrhoeaGastrointestinal disorders1/414/35
FatigueGeneral disorders1/414/35
InsomniaPsychiatric disorders0/413/35
DizzinessNervous system disorders0/413/35
NauseaGastrointestinal disorders0/413/35
HypertensionVascular disorders3/410/35
PneumoniaInfections and infestations0/412/35
SinusitisInfections and infestations0/412/35
DepressionPsychiatric disorders0/412/35
ConstipationGastrointestinal disorders0/412/35

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboDronedaroneTotal
Mean70.3 ± 8.274.1 ± 9.772.0 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDronedaroneTotal
Female151328
Male262248
08

Study locations

57 sites
  • Investigational Site Number 840072
    Phoenix, Arizona 85006, United States
  • Investigational Site Number 840015
    Little Rock, Arkansas 72204, United States
  • Investigational Site Number 840086
    Beverly Hills, California 90211, United States
  • Investigational Site Number 840018
    Loma Linda, California 92354, United States
  • Investigational Site Number 840029
    Merced, California 95348, United States
  • Investigational Site Number 840044
    Redwood City, California 94062, United States
  • Investigational Site Number 840042
    Santa Ana, California 92704, United States
  • Investigational Site Number 840060
    Vista, California 92083, United States
  • Investigational Site Number 840057
    Stamford, Connecticut 06905, United States
  • Investigational Site Number 840002
    Newark, Delaware 19713, United States
  • Investigational Site Number 840063
    Wilmington, Delaware 19808, United States
  • Investigational Site Number 840070
    Bradenton, Florida 34205, United States
  • Investigational Site Number 840010
    Jacksonville, Florida 32216, United States
  • Investigational Site Number 840071
    Jupiter, Florida 33458, United States
  • Investigational Site Number 840061
    Lakeland, Florida 33805, United States
  • Investigational Site Number 840096
    Lauderdale Lakes, Florida 33313, United States
  • Investigational Site Number 840031
    Ocala, Florida 34471, United States
  • Investigational Site Number 840074
    Orlando, Florida 32803, United States
  • Investigational Site Number 840016
    Ormond Beach, Florida 32174, United States
  • Investigational Site Number 840051
    St Petersburg, Florida 33709, United States
  • Investigational Site Number 840081
    Roswell, Georgia 30076, United States
  • Investigational Site Number 840103
    Jerseyville, Illinois 62052, United States
  • Investigational Site Number 840106
    Peoria, Illinois 61606, United States
  • Investigational Site Number 840066
    Elkhart, Indiana 46514, United States
  • Investigational Site Number 840099
    Lexington, Kentucky 40504, United States
  • Investigational Site Number 840039
    Owensboro, Kentucky 42303, United States
  • Investigational Site Number 840092
    Baton Rouge, Louisiana 70808, United States
  • Investigational Site Number 840040
    Auburn, Maine 04210, United States
  • Investigational Site Number 840077
    Ayer, Massachusetts 01432, United States
  • Investigational Site Number 840050
    Alpena, Michigan 49707, United States
  • Investigational Site Number 840041
    Saginaw, Michigan 48670, United States
  • Investigational Site Number 840058
    Minneapolis, Minnesota 55422, United States
  • Investigational Site Number 840101
    Picayune, Mississippi 39466, United States
  • Investigational Site Number 840078
    St Louis, Missouri 63122, United States
  • Investigational Site Number 840038
    St Louis, Missouri 63128, United States
  • Investigational Site Number 840102
    St. Louis, Missouri 63128, United States
  • Investigational Site Number 840012
    Kalispell, Montana 59901, United States
  • Investigational Site Number 840090
    Lincoln, Nebraska 68506, United States
  • Investigational Site Number 840003
    Bronx, New York 10468, United States
  • Investigational Site Number 840045
    Buffalo, New York 14215, United States
  • Investigational Site Number 840055
    Manhasset, New York 11030, United States
  • Investigational Site Number 840004
    Troy, New York 12180, United States
  • Investigational Site Number 840009
    Maumee, Ohio 43537, United States
  • Investigational Site Number 840028
    Camp Hill, Pennsylvania 17011, United States
  • Investigational Site Number 840067
    Wyomissing, Pennsylvania 19610, United States
  • Investigational Site Number 840027
    Wakefield, Rhode Island 02879, United States
  • Investigational Site Number 840046
    Knoxville, Tennessee 37917, United States
  • Investigational Site Number 840014
    Longview, Texas 75605, United States
  • Investigational Site Number 840068
    Danville, Virginia 24541, United States
  • Investigational Site Number 840069
    Manassas, Virginia 20109, United States
  • Investigational Site Number 840087
    Richmond, Virginia 23249, United States
  • Investigational Site Number 840085
    Winchester, Virginia 22601, United States
  • Investigational Site Number 840013
    Burien, Washington 98166, United States
  • Investigational Site Number 840091
    Spokane, Washington 99204, United States
  • Investigational Site Number 840080
    Madison, Wisconsin 53713, United States
  • Investigational Site Number 840023
    Milwaukee, Wisconsin 53215, United States
  • Investigational Site Number 124003
    Cambridge, Ontario, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2010
First posted
Sep 10, 2010
Start
Sep 2010
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
Feb 12, 2013
Last update
Feb 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01198873
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 10, 2010
Start date
Sep 2010
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Feb 12, 2013
Last update
Feb 12, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronedarone

Start the discussion